and mortality following HSCT, attributed to advances in posttransplant supportive care, organ support, HLA matching, and treatment of infectious diseases (2) . However, the risks of HSCT remain considerable, and with the steady increase in the number of HSCTs performed, the public health impact is substantial (3) .
Pulmonary complications are a major source of morbidity and mortality following HSCT (4) (5) (6) . These complications may be both infectious and noninfectious, often presenting with nonspecific diffuse lung infiltrates and hypoxemic respiratory failure. To better characterize these nonspecific presentations, a multitude of idiopathic and clinically overlapping lung injury syndromes have been described in the post-transplant period, including diffuse alveolar hemorrhage (7) (8) (9) , engraftment syndrome (10, 11) , and idiopathic pneumonia syndrome (5, 12, 13) . Crucially, in the absence of well-defined pathologic and diagnostic criteria, these syndromes often remain arbitrary and retrospective diagnoses of exclusion with limited clinical relevance at the time of initial hospital admission. Therefore, it may be more meaningful clinically to consider the severe end of the clinical spectrum of post-HSCT hypoxemic respiratory failure in the context of acute respiratory distress syndrome (ARDS), which has well-characterized clinical and pathophysiologic criteria, and may facilitate better understanding of the potentially devastating impact of respiratory failure following HSCT. To date, little data exist on the incidence and impact of developing ARDS in the post-transplant setting. In this retrospective cohort series, we evaluated the incidence of ARDS in all HSCTs performed between 2005 and 2012 at a single academic center.
MATERIALS AND METHODS
This investigation used a retrospective observational cohort study design. The study was approved by the Mayo Clinic Institutional Review Board (Rochester, Minnesota) prior to its initiation. The requirement for written informed consent was waived by the institutional review board. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were used in the conduct of this study as well as in the reporting of our results (14) .
Study Population
The study population was retrieved from a list of all patients who underwent autologous or allogeneic HSCT at Mayo Clinic Rochester, Minnesota, between January 1, 2005, and December 31, 2012. All patients aged 18 years or older and undergoing HSCT for any indication were included. For patients who underwent repeated HSCT, the first HSCT was used as the index event. Patients were excluded if they denied the use of their medical records for research or had a diagnosis of acute lung injury or ARDS at the time of HSCT (i.e., ARDS was diagnosed prior to the day donor cells were given to the recipient). Outcomes of patients with ARDS were compared with outcomes of those patients who underwent HSCT but did not develop ARDS. An additional analysis was performed comparing outcomes of patients with ARDS with those of patients admitted to an ICU without ARDS. To define this latter cohort, the first ICU admission greater than 24 hours in the year following HSCT was included for analysis. The study population is outlined in Figure 1 .
Outcome Variable
The primary outcome measure was the presence of ARDS within 1 year of transplant. ARDS was defined in accordance with the 2012 Berlin criteria as acute (within 1 wk of a known clinical insult) hypoxemic respiratory failure (arterial oxygen tension/fraction of inspired oxygen < 300 mm Hg) requiring positive end-expiratory pressure of 5 cm H 2 O or greater with bilateral opacities on chest imaging that are not fully explained by cardiac failure or fluid overload (15) .
The presence of ARDS was first identified by cross-referencing the database containing patients who have undergone HSCT with a second comprehensive database containing all patients who have screened positive for possible ARDS via a validated electronic syndrome surveillance tool known as the "ARDS sniffer." This automated system identifies patients who, within a 24-hr window, have 1) an arterial oxygen tension/fraction of inspired oxygen less than 300 mm Hg on arterial blood gas and 2) a chest radiograph report that contains the freetext Boolean terms ''edema'' or ''bilateral'' and ''infiltrate'' (16) . Where multiple arterial blood gas values exist, the worst value during the 24-hour window was selected. The ARDS sniffer has a negative predictive value of 99.6% (95% CI, 99.3%-99.8%) for identifying ARDS. Each screen-positive patient was independently reviewed by trained study investigators (H.Y., M.E.N., J.K.B.). Investigators underwent a structured ARDS tutorial prior to reviewing any data in the electronic medical record. All disagreements were referred to the senior investigator with substantial prior experience in ARDS adjudication (D.J.K.). Secondary outcome measures included in-hospital, 28-day, and 12-month mortality as well as hospital and ICU lengths of stay.
Data Retrieval
Data retrieval was performed with the help of a comprehensive institutional clinical research database, the Mayo Clinic Life Sciences System (MCLSS). MCLSS is a clinical data warehouse, developed in collaboration with Mayo Clinic and International Business Machines that allows automated clinical data extraction through a query tool called the "Data Discovery and Query Builder." Data were also retrieved through an institutional Microsoft Structured Query Language-based database that retrieves variables for all ICU patients in near real time (the "ICU datamart"). We have previously validated these data extraction techniques against manual data extraction (16) (17) (18) (19) (20) . The majority of these variables were obtained by using the validated search strategies described above. For variables lacking validated web-based extraction techniques, manual chart review was performed.
Statistical Analysis
Categorical variables were summarized as frequency (%) and compared by using chi-square tests or Fisher exact test, as appropriate. Continuous variables were expressed as mean ± sd when normally distributed or median with interquartile range (IQR) when nonparametric. Continuous variables were compared by using Student t tests for parametric data or Wilcoxon analysis for nonparametric data. Time-toevent data were analyzed with the Kaplan-Meier method, and the groups were compared with the use of the log-rank test. Trend analysis was performed by linear regression, with statistical significance determined by t statistic. In all final analyses, statistical significance was considered present when the twosided hypothesis test p value was less than 0.05. All statistical analyses were performed by using JMP version 10 (Cary, NC).
RESULTS
A total of 2,635 patients underwent first-time HSCT between January 1, 2005, and December 31, 2012 ( Fig. 1 ). Of these, 481 patients underwent allogeneic HSCT and 2,154 underwent autologous HSCT. The most common indication for allogeneic transplant was acute myeloid leukemia (180 of 481) and the most common indication for autologous HSCT was multiple myeloma (975 of 2,154) ( Table 1) .
ARDS Incidence and Outcomes Following HSCT
One hundred thirty-three of the 2,635 patients undergoing HSCT developed ARDS within 1 year of transplant, with a cumulative incidence of 5.0%. ARDS was more common following allogeneic HSCT, developing in 75 patients (15.6%) compared with 58 patients undergoing autologous HSCT (2.7%) (p < 0.001). The median time to ARDS development was 28.5 days (IQR, 11.9-133 d) following HSCT (Fig. 2) . The median time to ARDS development was significantly longer for those undergoing allogeneic HSCT (55.4 d; IQR, 15.1-139 d) compared with those undergoing autologous HSCT (14.2 d; IQR, 10.5-124 d; p = 0.03). For ARDS adjudication, interobserver κ was 0.66 (95% CI, 0.55-0.76).
Compared with those who did not develop ARDS following HSCT, the mortality of those developing ARDS was significantly higher at 28 days, 90 days, and 1 year ( Fig. 3 and Table 2 ). In patients who developed ARDS following HSCT, the mortality following transplant was generally higher for those undergoing allogeneic HSCT compared with those undergoing autologous HSCT. Specifically, mortality did not differ significantly at 28 days post-transplant but was significantly higher at 90 days post-transplant and at 1 year post-transplant. Following development of ARDS, ICU mortality was 38.3%, and hospital mortality was 57.1%. Twenty-eight-day mortality following ARDS diagnosis was 46.6% ( Table 3) . ICU length of stay was 7.9 days (IQR, 2.2-13.2 d) and hospital length of stay was 25.3 days (IQR, 11.0-44.1 d).
Outcomes were generally worse for patients following allogeneic transplantation compared with autologous transplantation (Table 3) . Compared with patients developing ARDS following autologous HSCT, patients developing ARDS following allogeneic HSCT were more likely to have more severe ARDS (p = 0.03), had longer ICU length of stays (allogeneic: 9 d [IQR, 3.3-15.0 d] vs autologous: 6.8 d [2.0-12.5]; p = 0.02), and had higher mortality in the ICU, hospital, and at 28 days (Table 3 ). There were no significant differences in hospital length of stay and ICU admission Acute Physiology and Chronic Health Evaluation (APACHE)-III or Sequential Organ Failure Assessment (SOFA) scores between the two groups. Among the 481 patients undergoing allogeneic transplantation, 215 (44.7%) received reduced intensity conditioning (RIC). Of those receiving RIC, 26 (12.1%) developed ARDS compared with 49 patients (18.4%) who received regular conditioning regimens (p = 0.06).
The incidence of ARDS was stable over time ( Table 4 ). There was no significant change in ICU mortality, in-hospital mortality, or 28-day mortality between 2005 and 2012. Severity of illness, assessed by SOFA and APACHE-III scores, was also stable over time. Although there was no change in ICU length of stay over time (p = 0.54), there was a significant decline in hospital length of stay (p = 0.02 for trend). A subgroup of patients developing ARDS met diagnostic criteria for the idiopathic noninfectious pulmonary syndromes following HSCT. Specifically, 7 of 133 ARDS cases (5.3%) met criteria for engraftment syndrome and 15 of 133 (11.3%) for diffuse alveolar hemorrhage. The remainder did not meet diagnostic criteria for one of the defined noninfectious pulmonary syndromes.
Outcomes of Patients Developing ARDS Compared
With HSCT Patients Admitted to ICU Without ARDS Of 2,635 patients undergoing HSCT, 540 patients were admitted to the ICU during the first year following transplantation ( ; p < 0.001). Other ARDS risk factors (polytrauma, pancreatitis, emergency surgery, or high-risk cardiac, aortic vascular, or thoracic surgery) were uncommon in both groups. Severity of illness was greater in the group that developed ARDS compared with the ICU admissions who did not. SOFA score on the day of admission was 10.7 ± 4.0 in the ARDS cohort compared with 6.0 ± 3.7 in the non-ARDS ICU cohort (p < 0.001). APACHE-III score was 97.8 ± 28.9 in the ARDS cohort compared with 78.1 ± 24.6 in the non-ARDS ICU cohort (p < 0.001). Outcomes were significantly worse in ICU admissions that developed ARDS compared with those who did not. Specifically, the ARDS cohort had longer ICU length of stays ( 
DISCUSSION
In this study, we defined the epidemiology and outcomes of ARDS following HSCT. The primary finding of this study is that the overall incidence of ARDS in the year following HSCT is 5.0%, with a higher incidence in those undergoing allogeneic HSCT compared with those undergoing autologous HSCT. The prognosis of those patients who develop ARDS following HSCT is poor, with a 1-year mortality of 66.8% compared with 11.8% in those who did not develop ARDS. A notable finding of our study was that the majority of patients developing ARDS following HSCT had pneumonia, sepsis, or shock prior to the development of ARDS, with just 4 of 133 patients with ARDS not having one of these three risk factors. This highlights the importance and ongoing impact of infectious complications following HSCT, despite recent improvements in the management of infectious diseases in the post-HSCT period (2) .
Pulmonary complications are a common source of morbidity and mortality in patients with hematologic malignancies who undergo HSCT (4, 5) . Such complications may be associated with a need for mechanical ventilation, extended ICU and hospital length of stays, concomitant organ failure, and death (21) . Little data exist regarding the epidemiology and outcomes of ARDS following HSCT. This study addresses that critical knowledge gap and helps better define the incidence and impact of ARDS in the post-HSCT setting. However, prior studies have provided some data on ARDS in patients with solid or hematologic malignancies in general. A post hoc subgroup analysis of patients in the ARDS Network trials noted that cancer patients with ARDS had a poorer outcome than those without ARDS (22) . In another post hoc retrospective analysis of clinical trials by the French and Belgian critical care trials group from 1990 to 2011, investigators identified over a thousand patients with ARDS and a history of malignancy (23) . In keeping with our study, the majority of patients with ARDS and malignancy had either a pulmonary or extrapulmonary infection prior to ARDS development, and prognosis was poor, with an in-hospital mortality of 64%. In a case series of patients with solid and hematologic malignancies that developed during a period of neutropenia following chemotherapy administration, mortality was again substantial, with a 28-day mortality rate of 63% (24) . However, just 14 of these patients had undergone prior HSCT at any point, and the timing of HSCT in relation to the development of ARDS was not specified. Although these studies highlight the important unmet need in the care of cancer patients with ARDS, our study provides the most rigorous and complete data to date, allowing us to define incidence and outcomes more comprehensively.
Although the impact of ARDS on patient-important outcomes remains substantial, data from the ARDS Network's randomized controlled trials suggests that the overall mortality from ARDS is declining (25) . This finding was mirrored at the enrolling site of the present investigation where we previously demonstrated a decline in ARDS-associated mortality between 2001 and 2008, despite increases in patient severity of illness and the prevalence of medical comorbidities (19) . Furthermore, the incidence of ARDS decreased by almost half, primarily the result of a decrease in hospital-acquired ARDS. This decline in mortality and incidence of ARDS has been attributed to numerous practice changes, including the institution of low tidal volume ventilation (26) , fluid-conservative resuscitation (27) , improved treatment of sepsis (28) , restrictive blood transfusion (29) , and institution of a male-predominant donor pool for plasma (30) . Although liketo-like comparisons can be challenging, the mortality following ARDS development in patients who have undergone HSCT in our study remains substantially higher than what has been reported in these other studies (19, 31) . Notably, our study did not show improvements in ARDS incidence or mortality over the 8-year study period, highlighting that improvements in ARDS outcomes in other clinical settings have not yet translated to the HSCT population.
Our results suggest that the majority of ARDS develops during or after the engraftment phase following HSCT. Engraftment generally occurs earlier following autologous transplantation than allogeneic, and ARDS development follows a similar time course (Fig. 2 ). In the minority of patients who develop ARDS during the neutropenic phase prior to engraftment, ARDS may occur through activation of alveolar macrophages (32) .
Further study is needed to analyze the specific risk factors for ARDS development in the HSCT population, including the presence of both known risk factors for ARDS such as sepsis, shock, drug-related lung toxicities, and pneumonia (18, 33) and yet undefined ARDS risk factors potentially unique to this population. For example, our study highlighted a trend toward lower incidence of ARDS in those patients receiving RIC chemotherapy regimens compared with patients receiving standard myeloablative regimens. Given the growing number of HSCT performed annually, the high morbidity and mortality associated with ARDS development ( Fig. 3 and Table 2) , and the substantial healthcare utilization associated with such complications, ARDS in the post-HSCT population has a major public health impact warranting further investigation.
Our study has a number of strengths that deserve mention. It is the first observational study to specifically evaluate the incidence, mortality, and other patient-important outcomes for patients who develop ARDS following HSCT. Defining the magnitude of the problem in this vulnerable and critically ill population is the crucial first step to further investigating ARDS in this clinical setting. Patients undergoing HSCT are a potentially fruitful population for ongoing investigation of ARDS prevention strategies as the clinical insult that results in ARDS (stem cell transplantation) is known in advance of developing the clinical syndrome of ARDS. This predictability may facilitate future trials evaluating promising ARDS prevention strategies. Given these patients often receive "multiple hits" in the post-transplant period, including transfusions, sepsis, shock, pneumonia, and other infections, future observational studies in this population could potentially identify the differential contribution of each of these risk factors in developing ARDS. This can facilitate the identification of potentially preventable exposures prior to the development of ARDS, with the goal of reducing the incidence and impact of ARDS in the post-HSCT period (34) . This study also used rigorous methods for ARDS adjudication and risk factor ascertainment when compared with prior studies.
Importantly, our study also has some limitations. The study population for this investigation was from a single academic medical center. This limited the overall sample size, the number of ARDS events, and consequently the overall precision of the results. This additionally raises concern for referral and institution-specific bias as well as overall generalizability. This study was retrospective, and consequently we discovered ARDS events only if they occurred at our institution, which would potentially exclude patients who developed ARDS elsewhere. However, most HSCT patients are closely followed at our institution in the year following transplant and frequently return if any post-transplant complications occur. Additionally, patients typically stay locally for the initial few months to facilitate the close clinical and laboratory monitoring required, and this is the time period where the majority of ARDS cases develop. Consequently, we feel that this study does capture the majority of ARDS cases that develop following HSCT. Nonetheless, since some cases Sequential Organ Failure Assessment score 10.7 ± 4.0 6.0 ± 3.7 < 0.001 HSCT = hematopoietic stem cell transplantation, ARDS = acute respiratory distress syndrome, N/A = not applicable.
